Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “CLAUDICATION”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 847 records · Page 47Linked to original sources
PubMed2000

Heart and carotid artery disease in stroke patients with intermittent claudication.

Much has been published on the natural history of intermittent claudication (IC), but little is known about the clinical features of stroke patients with IC. The purpose of this study was to examine clinical features and risk factors in stroke patients with or without IC, including heart disease and carotid artery disease. A hospital-based study was conducted of 3901 stroke patients, who were prospectively coded and entered into a computerized databank. Of these patients, 219 had symptoms of IC. Patients were subdivided by age into 10-year categories. There were at least 12 times more non-IC than IC patients in each category. An age-matched random sample was obtained containing 12 non-IC cases for each IC case, resulting in 219 cases of IC and 2628 non-IC cases. The prevalence of IC in the total stroke population was 5.6%. IC prevalence increased sharply with age until about 70 years. Cardiac ischaemia and internal carotid artery (ICA) disease were significantly more frequent in stroke with IC than without IC. IC patients also exhibited a higher prevalence of atherosclerotic disease as well as other risk factors such as smoking, hypercholesterolaemia, elevated haematocrit, and family history of stroke. Ischaemic heart disease and ICA disease are especially common in stroke with IC. IC, large artery disease and stroke share similar risk factors. IC symptoms in stroke patients may indicate extensive generalized atherosclerosis.

Adult↗
PubMed2002

Sulodexide in the treatment of intermittent claudication. Results of a randomized, double-blind, multicentre, placebo-controlled study.

AIMS: Patients with peripheral arterial obstructive disease require treatment to prevent major cardiovascular events and to relieve intermittent claudication. The walking performance of peripheral arterial obstructive disease patients was used to evaluate the usefulness of sulodexide, a glycosaminoglycan containing fast moving heparin and dermatan sulphate. METHODS AND RESULTS: A randomized, multicentre, double-blind, placebo-controlled study was performed in 286 patients with Leriche-Fontaine stage II peripheral arterial obstructive disease. Patients received placebo (n=143) or sulodexide (n=143) for 27 weeks. The primary end-point was the doubling of the pain-free walking distance at the end of treatment, and this was achieved by 23.8% of patients treated with sulodexide and 9.1% of those on placebo (P=0.001). The pain-free walking distance increased on average (+/-SE) by 83.2+/-8.6 m (+64.7% from baseline) with sulodexide and 36.7+/-6.2 m (+29.9% from baseline) with placebo (P=0.001). The maximum walking distance increased by 142.3+/-15.8 m (+76.0% from baseline) and 54.5+/-8.4 m (+27.9% from baseline) (P<0.001), respectively. Results for patients with type II diabetes were similar to those for non-diabetic patients. Plasma fibrinogen decreased with sulodexide, but increased with placebo. CONCLUSION: Sulodexide improved the walking ability of peripheral arterial obstructive disease patients to a significantly greater extent than placebo, with a concurrent significant decrease in fibrinogen. The treatment was well tolerated.

Aged↗
PubMed2000

Hemostasis and fibrinolysis in patients with intermittent claudication: effects of prostaglandin E1.

There is evidence that the coagulation system is activated in patients with peripheral arterial occlusive disease (PAOD). The beneficial effects of the vasoactive drug prostaglandin E1 (PGE1) may rely in part on the modulation of the coagulation system. The study was designed to evaluate the effects of PGE1 on hemostatic and fibrinolytic variables in patients with intermittent claudication. Therefore molecular markers of thrombin (prothrombin fragment 1+2, PTF 1+2; thrombin-antithrombin III complexes, TAT) and fibrin formation (fibrinopeptide A, FPA) and markers of the fibrinolytic activity (fibrin degradation products, D-dimers) were determined before and immediately after the first PGE1 dose (60 microg in 100 ml NaCl over 2 h i.v.) as well as after 4 weeks of daily infusion therapy in 12 PAOD patients and in eight control patients before and after a single placebo infusion. Plasma levels of PTF1+2, TAT, FPA and D-dimers tended to decrease after the initial dose of PGE1. Infusion therapy with PGE1 for 4 weeks led to a decrease of all hemostatic and fibrinolytic parameters with most pronounced changes for PFT1+2, D-dimers and plasminogen activator inhibitor-1 decreasing by 11% (P<0.05), 20% (P<0.05), and 7% (P<0.05), respectively. These variables remained unchanged in controls with placebo infusion. In summary, infusion therapy with PGE1 in patients with PAOD reduces thrombin formation and results in a decrease of fibrin degradation. PGE1 may thus reduce fibrin deposition involved in the pathogenesis of atherosclerosis.

Aged↗
PubMed1975

[Arterielle occlusion in two leg amputees ("phantom claudication" due to pelvic-artery stenosis) (author's transl)].

Signs of intermittent claudication in the phantom leg developed in two patients 18 and 27 years, respectively, after mid-thigh amputation. Symptomatic treatment of the phantom pain was without success. Clinical, oscillographic and angiographic studies demonstrated atherosclerotic arterial stenoses of the iliac arteries. After successful vascular reconstruction (iliac-femoral and aortic-femoral bypass, respectively) on the side of amputation both patients are without pain or other symptoms and can again walk with restriction.

Angiography↗
PubMed2005

Health inequalities among persons with type 2 diabetes: the example of intermittent claudication.

In Germany, high quality health care is offered to just about all socio-economic groups. The question is rarely asked, though, if there are social differences in the utilisation and quality of health care among those with similar needs. These differences are analysed by looking at a group of persons with type 2 diabetes mellitus. Another group of persons without diabetes is included as well. The data are taken from the KORA-A Study in Augsburg, southern Germany. KORA-A is a case-control study based on patients with type 2 diabetes from the MONICA surveys S2 (1989/90), S3 (1994/95) and the Myocardial Infarction Registry, and controls, matched by age and sex to the cases. In 1997/98, these persons were contacted for the KORA-A study. The dataset includes data from 378 type 2 diabetic patients. The group without diabetes comprises 438 persons. The results indicate that the prevalence of "pain while walking" increases with decreasing educational level, and that this association is stronger for persons with type 2 diabetes (OR 3.53; 95 % CI 1.32 - 9.44) than for persons without diabetes (OR 2.02; 95 % CI 0.97 - 4.23). The prevalence of intermittent claudication can serve as an indirect assessment of the quality of health care received by diabetic persons. It is concluded that health care should be improved especially for those persons with type 2 diabetes who belong to the group with low socioeconomic status.

Adult↗
PubMed1985

Mesenteric vascular insufficiency and claudication following acute dissecting thoracic aortic aneurysm.

Mesenteric vascular insufficiency and claudication of the left leg were observed in a patient 6 weeks after intraluminal aortic prosthesis placement for acute type III thoracic aortic dissection. Aortography revealed double-channel deformity of the thoracoabdominal aorta and complete occlusion of the celiac axis, inferior mesenteric artery, and left common iliac artery. An aortobi-iliac interposition graft placed end to end with an additional limb to the common hepatic artery was curative.

Acute Disease↗
PubMed2002

The impact of walking impairment, cardiovascular risk factors, and comorbidity on quality of life in patients with intermittent claudication.

OBJECTIVE: The objective of this study was to assess the impact of walking impairment, cardiovascular risk factors, and comorbidity on quality of life (QOL) in patients with intermittent claudication (IC). MATERIAL AND METHODS: The prospective observational study was conducted in the setting of a vascular outpatient department of a teaching hospital. QOL was assessed in 200 consecutive patients with IC, with a reduced version of the World Health Organization Quality of Life Assessment Instrument-100. The reduced instrument assesses 17 facets of QOL within five domains (Physical and Psychological Health, Level of Independence, Social Relationships, and Environment). Age, gender, degree of IC, risk factors, comorbidity, as recommended by the Society for Vascular Surgery/North American Chapter of the International Society for Cardiovascular Surgery (SVS/ISCVS), and the presence of back, hip, or knee symptoms were analyzed as possible predictors of QOL. Multiple regression analyses were run with each of the QOL facets and domains as dependent variable. A probability value of less than.05 was considered to be statistically significant. RESULTS: Male gender was found to be a predictor of better scores for Energy and Fatigue and for Sleep and Rest. Women had more Negative Feelings. The presence of back, hip, or knee symptoms was a significant predictive value for many aspects of QOL. With more concomitant diseases, patients had lower scores on the facets of Overall QOL and General Health and of Energy and Fatigue and showed more dependence on medication and treatments. The degree of IC, as expressed in the SVS/ISCVS classification, was a statistically significant predictor of QOL on the domain Level of Independence and its facets Mobility, Activities of Daily Living, and Working Capacity and the facets Pain and Discomfort, Sexual Activity, and Transport. Hypertension was the second most important single predictor of QOL in patients with IC. CONCLUSION: QOL in patients with IC is only partially determined by the severity of walking limitation as expressed in the SVS/ISCVS classification. The significant impact of cardiovascular risk factors and comorbidity and the presence of back, hip, or knee symptoms on QOL should be recognized and taken into account in the treatment policy.

Adult↗
PubMed2002

Pharmacologic therapy for peripheral arterial disease and claudication.

Peripheral arterial disease (PAD) is a common manifestation of systemic atherosclerosis that is associated with a high risk of cardiovascular mortality and significant limitation in function because of limb ischemia. Patients with PAD should be considered to have significant coronary and cerebral arterial disease that requires aggressive risk factor management, including the prescription of antiplatelet drugs, to lower the subsequent risk of myocardial infarction, stroke, and death. In the population with PAD, level 1 and level 2 evidence supports the use of statin drugs for lipid management, angiotensin-converting enzyme-1 inhibitors for blood pressure control, and aspirin or clopidogrel as antiplatelet agents. Once this is accomplished, the severity of limb symptoms should be assessed, and a structured exercise program or the selected use of drugs such as cilostazol to treat claudication should be prescribed. In patients primarily considered for surgical treatment, antiplatelet and anticoagulant drug therapy can be used as a means of promoting graft patency, and beta-adrenergic blockers can be used as a means of reducing the perioperative risks associated with vascular surgery.

Anticoagulants↗
PubMed2005

Effective training for patients with intermittent claudication.

OBJECTIVE: Current guidelines for treatment of intermittent claudication (IC) do not include a specific recommendation for the intensity of exercise therapy. Thus, the purpose of this study was to determine the relative effectiveness of high versus low intensity exercise for patients with IC, and further to study the effect of such training on blood flow to the legs during exercise. DESIGN: The effect of eight weeks of supervised endurance training was examined in 16 patients with IC. The patients were randomly assigned to training at intensities corresponding to either 60% or 80% of their peak oxygen consumption (VO2peak), respectively. RESULTS: VO2peak and time to exhaustion increased significantly (9% and 16%, respectively) more in the high intensity group (p<0.05). Blood flow to the legs did not change after training in any of the groups. CONCLUSION: High intensity training gave larger improvements in VO2peak and time to exhaustion than low intensity training. As blood flow did not change after the exercise program, it is likely that the observed different increase of VO2peak was due to changed mitochondrial oxidative capacity and/or skeletal muscle diffusive capacity.

Aged↗
PubMed1988

Epidemiology of intermittent claudication: evaluation of risk factors.

Information from a geriatric health screening programme (Dunedin Program) was used to study the prevalence and risk factors predisposing to intermittent claudication (IC) in 1704 ambulatory elderly subjects. Risk factors studied included reported symptoms and diseases, mediation use, haematological and biochemical findings. The prevalence of IC reported by Dunedin participants was 14.1% for women and 14.4% for men. There was a positive relationship between IC and the number of other diseases and symptoms reported (P less than 0.0001). Serum glucose, cholesterol, and triglycerides were significantly higher in subjects reporting IC. Systolic blood pressure was higher in men and women reporting IC, but no significant relationship was observed with diastolic blood pressure.

Aged↗
PubMed2005

Temporal trends in the incidence of intermittent claudication from 1950 to 1999.

Declines in coronary disease and stroke mortality have occurred, but it remains unclear whether intermittent claudication (IC) incidence and mortality rates have changed. The authors sought to examine long-term trends for IC in the community. Cases of IC among Framingham Study participants aged >or=40 years were classified according to date of onset from the 1950s to the 1990s. IC was defined as the presence of exertional calf discomfort that was relieved with rest. Age- and sex-adjusted incidence rate ratios were estimated using log-linear Poisson regression, and 10-year survival was calculated using the Kaplan-Meier method. IC occurred in 668 participants (286 women). The age- and sex-adjusted incidence rate of IC fell from 282 per 100,000 person-years during the period 1950-1969 to 225 per 100,000 person-years in the 1990s. The decline in IC incidence across time periods was significant (p for trend=0.01), with an initial increase in the 1970s being followed by declines of 16% in the 1980s and 18% in the 1990s. Approximately 40% of persons with IC died within 10 years of diagnosis, with no significant change occurring during the study period. IC incidence has declined since 1950, but mortality has remained high and unchanged. Factors contributing to the declining incidence of IC need clarification.

Adult↗
PubMed2001

Impaired balance and higher prevalence of falls in subjects with intermittent claudication.

BACKGROUND: The purpose of this study was to determine whether peripheral arterial disease (PAD) subjects have impaired balance and a higher prevalence of falls than non-PAD controls and to determine whether balance and falls are related to the severity of PAD and functional status. METHODS: A total of 367 PAD subjects (aged 68 +/- 1 years; mean +/- SEM) and 458 non-PAD controls (aged 67 +/- 1 years) were recruited. Unipedal stance time, history of ambulatory stumbling and unsteadiness, and history of falling were recorded. Additionally, subjects were characterized on age, ankle/brachial index (ABI), anthropometry, measured and self-reported ambulatory function, and monitored daily physical activity. RESULTS: Unipedal stance time was 28% shorter ( p <.001) in the PAD subjects than in the non-PAD controls (15.9 +/- 0.9 vs 22.1 +/- 1.0). History of ambulatory stumbling and unsteadiness was 86% more prevalent ( p <.001) in the PAD group (150/367 = 41%) than in the controls (101/458 = 22%), and history of falling was 73% more prevalent ( p <.001) in the PAD subjects (95/367 = 26%) than in the controls (69/458 = 15%). Within the PAD group, 6-minute walk distance, self-reported ambulatory function, and daily physical activity were significantly related to the balance and falling measures ( p <.05), whereas ABI was unrelated ( p >.05). CONCLUSIONS: Compared with the controls, PAD subjects with intermittent claudication had impaired balance and a greater likelihood of falling, both of which were associated with ambulatory function and daily physical activity.

Accidental Falls↗
PubMed2002

A rational approach to diagnosis and treatment of intermittent claudication.

Intermittent claudication (IC), the first recognizable symptom of peripheral arterial disease, is prevalent among older persons and associated with significant morbidity and mortality. The diagnosis of IC involves taking a thorough patient history, conducting a physical examination with an emphasis on the cardiovascular system, and noninvasive testing with functional assessment. The goals of treatment for IC are to prevent progression of vascular disease and cardiovascular complications and to improve exercise performance, functional status, and quality of life. The cornerstones of therapy are risk-factor modification, particularly smoking cessation, and exercise. In patients for whom non-pharmacologic therapy does not provide adequate pain relief and improvement in physical function, medical therapy with 1 of 2 drugs approved for the treatment of IC may be appropriate. Revascularization or intervention is generally reserved for patients with incapacitating disease. Early diagnosis of IC and implementation of effective therapy can reduce the development of morbidity and mortality.

Algorithms↗
PubMed2002

The effects of OP-1206 alpha-CD on walking dysfunction in the rat neuropathic intermittent claudication model.

UNLABELLED: IV prostaglandin E1 improves clinical symptoms in patients with spinal canal stenosis. In the present study, we assessed the effects of OP-1206 alpha-CD, an orally active prostaglandin E1 analog, on walking dysfunction in the rat neuropathic intermittent claudication model. To induce spinal stenosis, two pieces of silicon rubber were placed in the lumbar (L4-6) epidural space in rats. Postsurgical walking function was measured using a treadmill apparatus. Spinal cord blood flow (SCBF) and skin blood flow (SKBF) were measured using a laser-Doppler flowmeter. OP-1206 alpha-CD was administered orally bid for 11 days from postoperative Day 3. In Control nontreated rats, a significant walking dysfunction was observed from Day 1 after the induction of spinal stenosis and persisted for 14 days when compared with the Sham-Operated group. On postoperative Day 15, SCBF revealed a significant reduction in the territory of spinal stenosis, although SKBF was not affected. OP-1206 alpha-CD significantly improved walking dysfunction on postoperative Days 5 (300 microg/kg), 7 (150 and 300 microg/kg), and 14 (150 and 300 microg/kg) when compared with the Vehicle-Treated group. On postoperative Day 15, the decrease in SCBF was significantly (150 and 300 microg/kg) improved by OP-1206 alpha-CD treatment, albeit SKBF remained unaffected. These data show that oral treatment with OP-1206 alpha-CD is effective in improving walking dysfunction induced by spinal canal stenosis, and this therapeutic effect is likely mediated by improved SCBF at the territory of spinal stenosis. IMPLICATIONS: Intermittent motor dysfunction is a clinical symptom associated with partial spinal compression. The present study provides evidence that oral treatment with the prostaglandin E1 analog (OP-1206 alpha-CD) is effective in improving motor dysfunction and spinal cord blood flow in rats with spinal compression.

Alprostadil↗
PubMed1989

Chronic compartment syndrome. An unusual cause for claudication.

Chronic Compartment Syndrome (CCS) is usually caused by overuse injury in well-conditioned athletes (particularly runners). Less common causes of CCS include blunt trauma, venous insufficiency, and tumor. CCS is clinically manifested as claudication, tightness, and occasional paresthesia. Unlike other forms of overuse injury (tendonitis, stress fracture), CCS does not respond to rest, anti-inflammatory medications, or physical therapy. The diagnosis of this condition is confirmed by elevated compartment pressures (normal less than 15 mmHg; CCS greater than 20 mmHg). The only effective treatment is surgical compartment release. Two hundred nine patients have been surgically treated for CCS, 100 by subcutaneous fasciotomy (group I) and 109 by open fasciectomy (group II). These procedures were usually performed in ambulatory surgery using local anesthesia. Patients treated by open faciectomy instead of subcutaneous fasciotomy had fewer early postoperative wound complications (6% vs. 11%) and fewer late recurrences (2% vs. 11%).

Adult↗
PubMed2000

Prospective functional evaluation of the surgical treatment of neurogenic claudication in patients with lumbar spinal stenosis.

A prospective evaluation of patients with lumbar spinal stenosis undergoing operative treatment was performed using treadmill-bicycle functional testing as well as Oswestry and Visual Analog Pain scales for self-assessment. Thirty-two patients undergoing spinal stenosis decompression with and without a concomitant spinal fusion were prospectively evaluated, preoperatively and a minimum of 2 years postoperatively. Surgical treatment was demonstrated to produce significant improvement in walking ability, and to a lesser degree, in the ability to bicycle 2 years postoperatively. Improvement in patient function demonstrated on the Oswestry questionnaire correlated with decreased pain observed on the Visual Analog Pain scale. The treadmill-bicycle test appears to be a useful tool for the differential diagnosis of neurogenic claudication and may be used as an objective test of postoperative outcome.

Adult↗
PubMedDate not supplied

Effect of beta-blocking drugs on peripheral blood flow in intermittent claudication.

To determine the possible effects of beta-adrenergic blocking drugs on blood flow in arteriosclerotic peripheral vascular disease, we have measured muscle blood flow in eight patients with intermittent claudication who were taking beta-blocking drugs for mild uncomplicated hypertension. Patients completed daily, pindolol 5 mg three times daily, atenolol 100 mg daily, or placebo. Mean exercise muscle blood flow fell by approximately 30% after each active drug when compared to placebo. beta-Blocking drugs may be contraindicated in the presence of peripheral vascular disease. Cardioselectivity and partial agonist activity appear to confer no advantages in such patients.

Adrenergic beta-Antagonists↗